Viavi Solutions Inc. (VIAV)

Revance Therapeutics Stock Forecast

Stock Price Forecast

The 8 analysts that cover Revance Therapeutics stock have a consensus rating of "Buy" and an average price target of $12.69, which forecasts a 26.39% increase in the stock price over the next year. The lowest target is $8.00 and the highest is $16.

Price Target: $12.69 (+26.39%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$8.00	$12.69	$13.5	$16
Change	-20.32%	+26.39%	+34.46%	+59.36%

* Price targets were last updated on Jun 20, 2025.

Analyst Ratings

The average analyst rating for Revance Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Feb '25	Mar '25	Apr '25	May '25	Jun '25	Jul '25
Strong Buy	3	4	4	4	4	4
Buy	2	2	1	1	1	1
Hold	4	3	2	2	2	2
Sell	1	1	1	1	1	1
Strong Sell	0	0	0	0	0	0
Total	10	10	8	8	8	8

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Mike Genovese Rosenblatt	Rosenblatt	Strong Buy Maintains $14	Strong Buy	Maintains	$14	+34.46%	Jun 20, 2025
Andrew Spinola UBS	UBS	Hold Maintains $12 → $11	Hold	Maintains	$12 → $11	+9.56%	May 2, 2025
Dave Kang B. Riley Securities	B. Riley Securities	Hold Maintains $12 → $11	Hold	Maintains	$12 → $11	+9.56%	May 2, 2025
Mike Genovese Rosenblatt	Rosenblatt	Strong Buy Maintains $12 → $14	Strong Buy	Maintains	$12 → $14	+34.46%	May 2, 2025
Ryan Koontz Needham	Needham	Strong Buy Reiterates $15	Strong Buy	Reiterates	$15	+49.40%	May 2, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

1.10B

Increased by 9.96%

from 1.00B

Revenue Next Year

1.18B

Increased by 7.27%

from 1.10B

EPS This Year

0.46

from -0.12

EPS Next Year

0.55

Increased by 19.25%

from 0.46

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Jun 27, 2020	Jul 3, 2021	Jul 2, 2022	Jul 1, 2023	Jun 29, 2024	Jun 30, 2025	Jun 30, 2026	Jun 30, 2027
Revenue	1.14B	1.20B	1.29B	1.11B	1.00B	1.10B	1.18B	1.24B
Revenue Growth	0.53%	5.51%	7.80%	-14.42%	-9.56%	9.96%	7.27%	4.75%
EPS	0.21	0.29	0.07	0.11	-0.12	0.46	0.55	0.64
EPS Growth	970.39%	38.10%	-76.85%	63.87%	-	-	19.25%	16.16%
Forward PE	-	-	-	-	-	21.73	18.22	15.69
No. Analysts	-	-	-	-	-	11	11	6

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027
High	1.1B	1.3B	1.3B
Avg	1.1B	1.2B	1.2B
Low	1.1B	1.1B	1.2B

Revenue Growth

Revenue Growth	2025	2026	2027
High	13.6%	13.6%	9.5%
Avg	10.0%	7.3%	4.7%
Low	5.6%	0.7%	-0.4%

EPS Forecast

EPS	2025	2026	2027
High	0.48	0.61	0.75
Avg	0.46	0.55	0.64
Low	0.44	0.48	0.57

EPS Growth

EPS Growth	2025	2026	2027
High	-	31.8%	35.3%
Avg	-	19.3%	16.2%
Low	-	3.9%	3.2%

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.